Clinical Trials Directory

Trials / Unknown

UnknownNCT05198037

Clinical Implications of FKBP5 in Stroke

Clinical Implications of FKBP5 in Post-stroke Neural Plasticity and Neuromodulation Effects

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
500 (estimated)
Sponsor
Taipei Veterans General Hospital, Taiwan · Other Government
Sex
All
Age
20 Years – 80 Years
Healthy volunteers
Not accepted

Summary

With contemporary lifestyle changes and global aging, it is important yet unknown how stress interacts to post-stroke outcomes. This proposal aims to study the link between the stress-responsive FKBP51-related pathways and neural plasticity after stroke, elucidating FKBP5 gene polymorphisms and blood FKBP51 regulation in relation to brain excitability and functions, understanding the effects of transcranial direct current stimulation, and characterizing brain mechanisms for individualized early rehabilitation after stroke.

Detailed description

Stress is an underestimated risk factor and also a consequence of cardiovascular diseases and stroke. FK506-binding protein 51 (FKBP51) modulates stress responses by acting as a co-chaperone that negatively regulates glucocorticoid receptor (GR) to cortisol binding and nuclear signaling. In an oxygen-glucose deprivation (OGD) model of acute mouse hippocampal slices, FKBP5 deletion reduced ischemic neuronal hyperexcitation, and cathodal electrical stimulation of OGD-injured wild-type decreased FKBP51 levels. However, clinical implications of FKBP5 polymorphisms and FKBP51 regulation in post-stroke outcomes and neuromodulation-induced plasticity are unknown. We aim to assess the link between FKBP5 polymorphisms and blood FKBP51 regulation after stroke, and their relationship with stroke phenotypes, brain connectivity and functional outcomes.

Conditions

Interventions

TypeNameDescription
DEVICEBihemispheric tDCSThe anode and cathode are placed over the ipsilesional and contralesional primary motor cortex (C3 or C4 based on 10-20 system), respectively. The size of the electrode is 5x5 cm.

Timeline

Start date
2021-11-01
Primary completion
2025-07-01
Completion
2025-07-01
First posted
2022-01-20
Last updated
2022-01-20

Locations

1 site across 1 country: Taiwan

Source: ClinicalTrials.gov record NCT05198037. Inclusion in this directory is not an endorsement.